Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
103.02
+1.64 (1.62%)
At close: Aug 1, 2025, 4:00 PM
103.98
+0.96 (0.93%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.

The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation.

Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.
Axsome Therapeutics logo
CountryUnited States
Founded2012
IPO DateNov 19, 2015
IndustryBiotechnology
SectorHealthcare
Employees683
CEOHerriot Tabuteau

Contact Details

Address:
One World Trade Center, 22nd Floor
New York, New York 10007
United States
Phone212 332 3241
Websiteaxsome.com

Stock Details

Ticker SymbolAXSM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001579428
CUSIP Number05464T104
ISIN NumberUS05464T1043
Employer ID45-4241907
SIC Code2834

Key Executives

NamePosition
Dr. Herriot Tabuteau M.D.Founder, Chairman, Chief Executive Officer and President
Nick Pizzie CPA, M.B.A.Chief Financial Officer
Mark L. Jacobson M.A.Chief Operating Officer
Hunter Murdock Esq.General Counsel and Secretary
Ari MaizelChief Commercial Officer
Darren OplandDirector of Corporate Communications

Latest SEC Filings

DateTypeTitle
Jun 23, 2025144Filing
Jun 20, 2025144Filing
Jun 18, 2025144Filing
Jun 17, 2025144Filing
Jun 16, 2025144Filing
Jun 10, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
Jun 9, 2025144Filing
Jun 9, 20258-KCurrent Report
May 28, 2025144Filing